EVEROLIMUS
Application
Everolimus has been used as an mechanistic target of rapamycin complex 1 (mTORC1) inhibitor to study its effect on MCF7 and MDA-MB-231 cell lines.
Biochem/physiol Actions
Everolimus, the 40-O-(2-hydroxyethyl) derivative of rapamycin (sirolimus), is a potent and selective inhibitor of mechanistic target of rapamycin (mTOR). Everolimus is selective for the mTORC1 protein complex. Everolimus exhibit potent immunosuppressive and anticancer activities.
Everolimus, a substrate for P-glycoprotein (P-gp) can be used to treat advanced neuroendocrine tumors (NETs).
| Colour | white to beige |
|---|---|
| InChI key | HKVAMNSJSFKALM-GKUWKFKPSA-N |
| InChI | 1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29 |
| Manufacturer | SIGMA-ALDRICH |
| Form | powder |
| Assay | ≥95% (HPLC) |
There are no downloads for this product.
